GURUFOCUS.COM » STOCK LIST » Real Estate » Real Estate » Lushang Freda Pharmaceutical Co Ltd (SHSE:600223) » Definitions » Change In Receivables

Lushang Freda Pharmaceutical Co (SHSE:600223) Change In Receivables : ¥0 Mil (TTM As of Mar. 2024)


View and export this data going back to 2000. Start your Free Trial

What is Lushang Freda Pharmaceutical Co Change In Receivables?

Lushang Freda Pharmaceutical Co's change in receivables for the quarter that ended in Mar. 2024 was ¥0 Mil. It means Lushang Freda Pharmaceutical Co's Accounts Receivable stayed the same from Dec. 2023 to Mar. 2024 .

Lushang Freda Pharmaceutical Co's change in receivables for the fiscal year that ended in Dec. 2023 was ¥1,861 Mil. It means Lushang Freda Pharmaceutical Co's Accounts Receivable declined by ¥1,861 Mil from Dec. 2022 to Dec. 2023 .

Lushang Freda Pharmaceutical Co's Accounts Receivable for the quarter that ended in Mar. 2024 was ¥502 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Lushang Freda Pharmaceutical Co's Days Sales Outstanding for the three months ended in Mar. 2024 was 51.44.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Lushang Freda Pharmaceutical Co's liquidation value for the three months ended in Mar. 2024 was ¥2,188 Mil.


Lushang Freda Pharmaceutical Co Change In Receivables Historical Data

The historical data trend for Lushang Freda Pharmaceutical Co's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lushang Freda Pharmaceutical Co Change In Receivables Chart

Lushang Freda Pharmaceutical Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Change In Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 411.03 -1,284.69 2,031.83 523.12 1,861.32

Lushang Freda Pharmaceutical Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Lushang Freda Pharmaceutical Co Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Lushang Freda Pharmaceutical Co  (SHSE:600223) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Lushang Freda Pharmaceutical Co's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=502.082/890.637*91
=51.44

2. In Ben Graham's calculation of liquidation value, Lushang Freda Pharmaceutical Co's accounts receivable are only considered to be worth 75% of book value:

Lushang Freda Pharmaceutical Co's liquidation value for the quarter that ended in Mar. 2024 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=3241.171-1694.606+0.75 * 502.082+0.5 * 529.064
=2,188

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Lushang Freda Pharmaceutical Co Change In Receivables Related Terms

Thank you for viewing the detailed overview of Lushang Freda Pharmaceutical Co's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.


Lushang Freda Pharmaceutical Co (SHSE:600223) Business Description

Traded in Other Exchanges
N/A
Address
No. 9777 Jingshi Road, Building 5, Lixia District, Jinan City, CHN
Lushang Freda Pharmaceutical Co Ltd formerly Lushang Health Industry Development Co Ltd is a real estate developer in China. The company is engaged in the development of office buildings, infrastructure, apartments, and hotels.
Executives
Li Hang senior management
Yin Wei Directors, senior managers
Shao Zhao Wei senior management
Wang Zhong Wu senior management
Dong Hong Lin Director
Zhou Hong Bo senior management
Li Lu senior management
Liu Zeng Wei senior management
Zhang Quan Li senior management
Xu Tao senior management
Ju Hai Bo Director
Zhao Xi Liang Director
Pi Xi Cai Supervisors

Lushang Freda Pharmaceutical Co (SHSE:600223) Headlines

No Headlines